Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 19.00, indicating a potential upside of 26% from the current price of HKD 15.10 [1][9]. Core Insights - The company achieved a revenue of RMB 410.7 billion in 2024, a slight decrease of 0.8% year-over-year (YOY), while the net profit attributable to shareholders was RMB 27.7 billion, reflecting a growth of 16.1% YOY [9]. - The pharmaceutical segment, which constitutes 70.7% of the product mix, saw a revenue decline of 4.3% due to a drop in sales of COVID-related and anti-infection drugs, but innovative oncology and immunomodulatory products showed a growth of 6% [9]. - The company plans to distribute a cash dividend of RMB 3.20 per 10 shares, resulting in a dividend yield of approximately 2.3% for H shares [9]. - The company has a robust pipeline with over 80 projects in development, including self-developed and licensed products, which are expected to drive future growth [9]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology industry, with a market capitalization of HKD 83.34 billion and a share price/book value ratio of 0.79 [2]. Financial Performance - In 2024, the company reported a net profit of RMB 27.7 billion, with a significant increase in operating cash flow to RMB 33.8 billion, up 31% YOY [9]. - The gross margin for the year was 48.0%, a slight increase of 0.2 percentage points, while the expense ratio decreased by 3.8 percentage points to 43.1% [9]. Future Projections - The company is expected to achieve net profits of RMB 33 billion, RMB 39 billion, and RMB 46 billion for the years 2025, 2026, and 2027, respectively, with YOY growth rates of 20.5%, 17.6%, and 17.3% [11]. - The earnings per share (EPS) are projected to be RMB 1.3, RMB 1.5, and RMB 1.7 for the same years, corresponding to H share price-to-earnings (P/E) ratios of 11X, 10X, and 8X, indicating undervaluation [11].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 19.00, indicating a potential upside of 26% from the current price of HKD 15.10 [1][9]. Core Insights - The company achieved a revenue of RMB 410.7 billion in 2024, a slight decrease of 0.8% year-over-year (YOY), while the net profit attributable to shareholders was RMB 27.7 billion, reflecting a growth of 16.1% YOY [9]. - The pharmaceutical segment, which constitutes 70.7% of the product mix, saw a revenue decline of 4.3% due to a drop in sales of COVID-related and anti-infection drugs, but innovative oncology and immunomodulatory products showed a growth of 6% [9]. - The company plans to distribute a cash dividend of RMB 3.20 per 10 shares, resulting in a dividend yield of approximately 2.3% for H shares [9]. - The company has a robust pipeline with over 80 projects in development, including innovative drugs and biosimilars, which are expected to drive future growth [9]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology industry, with a market capitalization of HKD 83.34 billion and a share price-to-book ratio of 0.79 [2]. Financial Performance - In 2024, the company reported a net profit of RMB 27.7 billion, with a significant increase in operating cash flow to RMB 33.8 billion, up 31% YOY [9]. - The gross margin for the year was 48.0%, a slight increase of 0.2 percentage points, while the expense ratio decreased by 3.8 percentage points to 43.1% [9]. Future Projections - The company is expected to achieve net profits of RMB 33 billion, RMB 39 billion, and RMB 46 billion for the years 2025, 2026, and 2027, respectively, with YOY growth rates of 20.5%, 17.6%, and 17.3% [11]. - The earnings per share (EPS) are projected to be RMB 1.3, RMB 1.5, and RMB 1.7 for the same years, corresponding to H share price-to-earnings ratios of 11X, 10X, and 8X, indicating undervaluation [11].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to 35% [5][11]. Core Insights - The company achieved a revenue of RMB 1.35 billion in 2024, representing a year-over-year (YOY) increase of 23.1%, and a net profit of RMB 270 million, with a YOY growth of 50.4% [8]. - The company is expected to continue its rapid growth in the first half of 2025, with projected net profits of RMB 350 million, reflecting a YOY increase of 28.8% [8][10]. - The company has seen significant recovery in revenue from hip and knee joint replacement products following the renewal of centralized procurement contracts, with hip joint revenue growing by 23.5% and knee joint revenue by 30.1% [8]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology industry, with a current H-share price of HKD 5.62 and a target price of HKD 7.3 [2][5]. Financial Performance - The company reported a comprehensive gross margin of 60.0% for 2024, with a net profit margin of 20.3%, an increase of 3.7 percentage points YOY [8]. - The earnings per share (EPS) for 2025 is projected to be RMB 0.31, with a corresponding price-to-earnings (P/E) ratio of 17x [10]. Revenue Breakdown - The revenue composition includes 55% from hip joint implants, 30% from knee joint implants, 10% from spinal and trauma implants, and 4% from customized products and services [3]. Future Projections - The company is expected to achieve net profits of RMB 440 million and RMB 526 million in 2026 and 2027, respectively, with growth rates of 24.9% and 19.4% [10].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [5][11]. Core Insights - The company is expected to achieve a net profit of RMB 2.7 billion in 2024, reflecting a year-over-year increase of 50.4%, which aligns with market expectations [6][8]. - Revenue for 2024 is projected to be RMB 13.5 billion, representing a year-over-year growth of 23.1% [8]. - The company anticipates significant revenue growth in the second half of 2024, with expected revenue of RMB 6.9 billion, a year-over-year increase of 54.8% [8]. - The company plans to distribute a dividend of HKD 0.072 per share [8]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology sector, with a current H-share price of HKD 5.62 and a target price of HKD 7.3 [2][5]. Financial Performance - The company reported a comprehensive gross margin of 60.0% for 2024, with a net profit margin of 20.3%, an increase of 3.7 percentage points year-over-year [8]. - The revenue breakdown shows that hip joint replacement implants account for 55% of total revenue, knee joint replacement implants for 30%, spinal and trauma implants for 10%, and custom products and services for 4% [3][8]. Earnings Forecast - The company is projected to achieve net profits of RMB 3.5 billion, RMB 4.4 billion, and RMB 5.3 billion for the years 2025, 2026, and 2027, respectively, with year-over-year growth rates of 28.8%, 24.9%, and 19.4% [8][10]. - The earnings per share (EPS) are expected to be RMB 0.31, RMB 0.39, and RMB 0.47 for the same years [10]. Market Position - The company has a market share of approximately 20% in the joint replacement market and has seen an increase in contributions from tier 1 hospitals [8].

2025 年 3 月 26 日 | H70507@capital.com.tw | | --- | | 费倩然 目标价(元) 27.5 | 公司基本资讯 | 产业别 | | 化工 | | --- | --- | --- | | A 股价(2025/3/26) | | 23.52 | | 上证指数(2025/3/26) | | 3368.70 | | 股价 12 个月高/低 | | 24.89/17.41 | | 总发行股数(百万) | | 1834.33 | | A 股数(百万) | | 1834.33 | | A 市值(亿元) | | 431.43 | | 主要股东 | | 云天化集团有 | | | | 限责任公司 | | | | (38.12%) | | 每股净值(元) | | 12.19 | | 股价/账面净值 | | 1.93 | | | 一个月 三个月 | 一年 | | 股价涨跌(%) | 13.9 | 3.6 29.0 | | 近期评等 | | | | 出刊日期 | 前日收盘 | 评等 | | 2024.08.12 | 19.66 | 买进 | | 产品组合 | | | --- | --- | | ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside in the stock price [6][12]. Core Insights - The company reported a revenue of 61.54 billion RMB for 2024, a year-over-year decrease of 10.89%, while net profit increased by 17.93% to 5.33 billion RMB, benefiting from an improved gross margin [7]. - The company announced a dividend of 1.4 RMB per share, resulting in a dividend payout ratio of 48.15%, which is an increase from 40.56% in 2023, highlighting a commitment to shareholder returns [7][13]. - The company is focusing on its core chemical business, reducing the proportion of low-margin trading activities, which has positively impacted its gross margin [8]. Financial Performance - For 2024, the company achieved a gross margin of 17.50%, an increase of 2.32 percentage points year-over-year, supported by stable prices for phosphate products and a decrease in raw material costs [8]. - The company’s earnings per share (EPS) for 2024 is projected at 2.91 RMB, with a forecasted net profit of 5.33 billion RMB, reflecting a year-over-year growth of 17.93% [11]. - The company’s price-to-earnings (P/E) ratio is projected to be 8.09 for 2024, indicating a reasonable valuation [11]. Market Outlook - The report anticipates that fertilizer prices will rise in Q1 2025 due to the spring planting season, which could further enhance the company's profitability [8]. - The average price of phosphate rock is expected to remain stable, supporting the pricing of phosphate chemical products [8]. - The company is expected to maintain a strong market position in the phosphate and fertilizer industry, leveraging its integrated operations and resource advantages [7].

Investment Rating - The report assigns a "BUY" rating to the company, indicating a potential upside in the stock price [5][10]. Core Insights - The company achieved a revenue of RMB 13.04 billion for the year, representing a year-on-year increase of 107%, and recorded a net profit of RMB 3.13 billion, which is a 189% increase year-on-year, exceeding expectations [5]. - The company has seen strong growth in both domestic and international markets, with domestic revenue reaching RMB 7.97 billion (up 52.3% year-on-year) and international revenue reaching RMB 5.07 billion (up 375.2% year-on-year) [7]. - The company has demonstrated exceptional IP operational capabilities, with four major IPs generating over RMB 1 billion in revenue each [7]. - The gross profit margin increased by 5.47 percentage points to 66.79%, benefiting from a higher proportion of overseas revenue and effective supply chain cost control [7]. - The company is expected to continue focusing on IP development and product launches, enhancing consumer recognition and emotional ties with fans, which will drive further growth in both domestic and international markets [7]. Financial Summary - The company reported a net profit of RMB 3.13 billion for 2024, with projections of RMB 4.57 billion, RMB 5.77 billion, and RMB 6.95 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 46.4%, 26.1%, and 20.4% [9]. - The earnings per share (EPS) are projected to be RMB 3.41, RMB 4.30, and RMB 5.17 for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (P/E) ratios of 34x, 27x, and 23x [9]. - The company plans to distribute a dividend of RMB 0.8146 per share [5].

Investment Rating - The report assigns a "BUY" rating for the company, indicating a potential upside in the stock price [5][10]. Core Insights - The company achieved a revenue of RMB 13.04 billion for the year, representing a year-on-year increase of 107%, and recorded a net profit of RMB 3.13 billion, which is a 189% increase year-on-year, exceeding expectations [5]. - The company has seen strong growth in both domestic and international markets, with domestic revenue reaching RMB 7.97 billion (up 52.3% year-on-year) and international revenue at RMB 5.07 billion (up 375.2% year-on-year) [7]. - The company has demonstrated exceptional IP operational capabilities, with four major IPs generating over RMB 1 billion in revenue each [7]. - The gross profit margin increased by 5.47 percentage points to 66.79%, benefiting from a higher proportion of overseas revenue and effective supply chain cost control [7]. - The company is expected to continue focusing on IP development and product launches, enhancing consumer recognition and emotional ties with fans, which will drive further growth in both domestic and international markets [7]. Summary by Sections Financial Performance - The company reported a net profit of RMB 3.13 billion for 2024, with projections of RMB 4.57 billion, RMB 5.77 billion, and RMB 6.95 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 46.4%, 26.1%, and 20.4% [9]. - The earnings per share (EPS) are projected to be RMB 3.41, RMB 4.30, and RMB 5.17 for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (P/E) ratios of 34x, 27x, and 23x [9]. Revenue Breakdown - The revenue composition includes 53.2% from figurines, 21.7% from plush toys, 12.9% from MEGA products, and 12.2% from derivatives and others [3]. Dividend Policy - The company plans to distribute a dividend of RMB 0.8146 per share [5].

m 2024 年 2 月 14 日 沈嘉婕 H70455@capital.com.tw 目标价(元/港元) 442RMB/467HKD 公司基本资讯 | 产业别 | 汽车 | | --- | --- | | H 股价(2025/03/25) | 389.20 | | 恒生指数(2025/03/25) | 23,344.3 | | 股价 12 个月高/低 | 424.2/194.55 | | 总发行股数(百万) | 3,039.07 | | H 股数(百万) | 1,227.80 | | H 市值(亿元) | 7,325.53 | | 主要股东 | 王传福 | | | (16.93%) | | 每股净值(元) | 58.56 | | 股价/账面净值 | 6.65 | | | 一个月 三个月 一年 | | 股价涨跌(%) | 0.05% 44.26% 88.68% | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025-2-14 | 341.3 | 买进 | | 产品组合 | | | | 汽车业务 | | 79.5% | 股价相对大盘走势 C o m p a ...

m 2024 年 2 月 14 日 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025-2-14 | 341.3 | 买进 | | 产品组合 | | | | 汽车业务 | | 79.5% | 股价相对大盘走势 C o m p a n y U p d a t e C h i n a R e s e a r c h D e p t . 沈嘉婕 H70455@capital.com.tw 目标价(元/港元) 442RMB/467HKD 比亚迪(01211.HK /002594.SZ) Buy 买进 公司基本资讯 公司 2024 年净利润 YOY+34%，销量保持高增，建议"买进" | 产业别 | 汽车 | | --- | --- | | H 股价(2025/03/25) | 389.20 | | 恒生指数(2025/03/25) | 23,344.3 | | 股价 12 个月高/低 | 424.2/194.55 | | 总发行股数(百万) | 3,039.07 | | H 股数(百万) | 1,227.80 | | H 市值(亿元) | 7,325.53 | | 主要股东 ...